Story
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
The Full Story
Waaree Energies transformed from a low-margin module assembler into India's largest integrated solar manufacturer in under four years, riding a combination of government policy tailwinds, US export demand, and aggressive backward integration. Management's narrative evolved from "we make cheap solar panels" to "we are the energy transition platform" — and margins followed, expanding from 4% to 25%. The credibility question is no longer whether they can grow, but whether the Waaree 2.0 diversification story (batteries, hydrogen, transformers, inverters) will deliver returns anywhere close to the solar core, and whether the US regulatory overhang will become material.
1. The Narrative Arc
The inflection point was FY2023: US export demand surged under anti-dumping pressures against Chinese/SE Asian modules, and Waaree's India-origin products became attractive. Revenue jumped from $38M to $82M in a single year. But the real structural shift came in FY2025-26 when backward integration into cells started compressing input costs, and DCR (Domestic Content Requirement) policy created a protected premium market for Indian-made cells.
The Q3 FY25 margin jump from 15% to 21% was the moment the story changed. It coincided with falling cell input costs and management's shift toward "choosing profitable orders." Every quarter since has held or expanded.
2. What Management Emphasized — and Then Stopped Emphasizing
What rose: "EBITDA as North Star" did not exist before Q4 FY25. Once management gave formal guidance ($643-702M), it became the single most repeated phrase in every subsequent call. The DCR/ALMM theme escalated as cell capacity came online — it went from background policy to a core margin driver.
What faded: The "multi-decadal growth story" framing — repeated four times in the maiden Q2 FY25 call — gradually became assumed rather than argued. IRA discussion peaked when Trump won in late 2024, then management deliberately steered away: "we don't bake in PLI" became the talking point, and IRA was reframed as "cherry on the top."
The quiet pivot: Export mix. In Q2 FY25, management acknowledged exports dropped from 60% to 27% of sales and called it "just a point in time" and "definitely not because of competition." By Q4 FY25, they repositioned the domestic-heavy mix as strategic: 80% domestic, 17-22% exports, and framed it as a feature rather than a limitation.
3. Risk Evolution
The risk profile has shifted dramatically. In FY25, the dominant investor concern was IRA removal under Trump. Management neutralized this by (a) positioning the US factory as "making in America for America" and (b) demonstrating 80% domestic revenue. By Q3 FY26, IRA had faded and two new risks emerged:
AD/CVD investigation (new): CBP probe into cell sourcing for US-bound modules. Management acknowledged it openly, provisioned $33M proactively, and stated "our internal review suggests we may not be facing a whole host of liabilities." The proactive provisioning was a credibility-positive move.
Silver/commodity prices (new): Q3 FY26 brought sharp investor questions about silver (25% of cell cost) and China export-rebate removal pushing cell prices from ¢4-4.5 to ¢6. Management response: "less than 9% on a module basis" and offset by operating leverage. This risk was not discussed before FY26.
4. How They Handled Bad News
The export mix collapse (Q2 FY25): Exports dropped from 60% to 27% of sales. CEO Amit Paithankar: "The reduction is definitely not because of competition. It is actually just a point in time." This was partially honest — the order book was 72% US — but it sidestepped that US execution timelines were 1-2 years out. By Q3 FY25, as domestic margins improved sharply, the narrative shifted to this being a superior mix.
Cell factory ramp-up delays: Promised 1.4 GW by Dec 2024, full 5.4 GW by March 2025. Reality: by Q2 FY26, cell utilization was still under 15% on a quarterly basis. Management consistently framed it as "ramp-up changes almost on a daily basis" and by Q3 FY26 said "most of the teething trouble is behind us" with current run-rate at 80%. The 9-month lag between COD and meaningful utilization was never acknowledged as a delay.
US AD/CVD probe (Q2-Q3 FY26): Handled well. Acknowledged transparently: "I definitely confirm that the probe is on." Provisioned $33M on lawyer advice before any demand was raised. This was the most credibility-enhancing moment in the transcript record.
5. Guidance Track Record
Credibility Score (1-10)
Management consistently delivers on financial outcomes (margins, EBITDA) but has a pattern of optimistic timelines on manufacturing ramp-ups. The cell factory was declared "commercially operational" months before meaningful utilization materialized. The EBITDA guidance, however, has been the strongest credibility anchor — given in Q4 FY25 at $643-702M and on track to be exceeded with 9M at $489M.
6. What the Story Is Now
The current narrative is "Waaree 2.0" — a transition from India's largest solar module maker into an integrated energy transition platform spanning polysilicon (Oman JV), ingots/wafers, cells, modules, inverters, transformers, batteries (20 GWh), green hydrogen (1 GW electrolyser), and power infrastructure (6.1 GW connectivity secured).
What has been de-risked:
The core solar manufacturing business. OPM expanded from 4% to 25% over five years, and the EBITDA guidance delivery builds institutional credibility
Cell backward integration. Despite slow ramp, own cells now running at 80% utilization and feeding DCR market at higher margins (300-350 bps uplift)
US manufacturing presence. 2.6 GW module capacity in US (including Meyer Burger acquisition) provides tariff hedge
Order book visibility. $6.4B with 5-15% advances and 65% overseas, providing 2+ years of revenue visibility
What still looks stretched:
The Waaree 2.0 diversification. $2.7B+ capex into BESS, hydrogen, transformers, smart meters — all pre-revenue. Management says payback in 3-5 years with "similar ROCE" but has zero operating history in these segments
Capital allocation discipline. Acquisitions accelerating (Enel, Kotsons, Racemosa, Meyer Burger) while core capex is $2.7B+. Management declined to give FY27 EBITDA guidance
US regulatory tail risk. AD/CVD probe ongoing, $33M provisioned, and US anti-dumping duties on Indian solar announced Apr 2026. The 14% + 26% tariff structure creates ongoing uncertainty for India-to-US exports
Cell/ingot-wafer execution. 10 GW cell + 10 GW ingot-wafer by FY27 is ambitious. Each GW of cell takes 4-6 months to ramp per management's own admission
What to believe vs. discount:
Believe: The India domestic solar story. 35 GW installed in 9M FY26, heading to 60-70 GW annually by decade end. Waaree's 14% market share, DCR cell advantage, and 400+ retail channels position it well
Believe: The EBITDA guidance. Management has earned credibility here and the 9M trajectory supports it
Discount: Revenue/margin projections for BESS, hydrogen, transformers. These are embryonic and management itself says "to give you hard numbers which are of audit grade will probably not be possible"
Watch: US revenue share. Currently 17-22% of sales but 55-65% of order book. How this converts — and at what margin after tariffs — is the key swing variable for FY27-28